K. Reich

发表

Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab

A. Armstrong, K. Reich, P. Foley, 2020, The Journal of dermatological treatment.

Anxiety and depression in patients with moderate‐to‐severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study

K. Reich, P. Foley, Chenglong Han, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations

P. Gisondi, K. Reich, E. D. De Jong, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies

A. Gottlieb, M. Lebwohl, K. Reich, 2020, The British journal of dermatology.

S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update

H. Orzechowski, K. Reich, M. Sebastian, 2012, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta‐analysis of randomized controlled trials

K. Reich, N. Hawkins, N. Hawkins, 2012, The British journal of dermatology.

German S3-guidelines on the treatment of psoriasis vulgaris (short version)

H. Orzechowski, K. Reich, B. Rzany, 2012, Archives of Dermatological Research.

S3 – Guidelines on the treatment of psoriasis vulgaris Update 2011

H. Orzechowski, K. Reich, M. Sebastian, 2011 .

European S3‐Guidelines on the systemic treatment of psoriasis vulgaris

L. Naldi, H. Hönigsmann, M. Hussain, 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases

K. Reich, D. Thaçi, R. Mössner, 2008, Archives of Dermatological Research.

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)

H. Orzechowski, K. Reich, B. Rzany, 2007, Archives of Dermatological Research.

Epidemiology and Comorbidity in Children with Psoriasis and Atopic Eczema

I. Schaefer, K. Reich, M. Augustin, 2015, Dermatology.

Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database

B. Strober, D. Gladman, A. Deodhar, 2018, The British journal of dermatology.

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

M. Lebwohl, J. Erickson, A. Menter, 2015, The Lancet.

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.

K. Reich, A. Blauvelt, C. Leonardi, 2016, Journal of the American Academy of Dermatology.

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

E. H. Thompson, M. Gooderham, K. Reich, 2019, The Lancet.

Photodynamic therapy with BF‐200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double‐blind, placebo‐controlled phase III study

U. Reinhold, K. Reich, M. Sebastian, 2010, The British journal of dermatology.

Cytokine gene polymorphisms in allergiccontact dermatitis

I. König, A. Ziegler, A. Schnuch, 2003, Contact dermatitis.

A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.

J. Ortonne, K. Papp, K. Reich, 2011, The New England journal of medicine.

Ten years of infliximab: its role in dermatology.

K. Reich, U. Mrowietz, 2009, European journal of pharmacology.

Ustekinumab for the treatment of plaque psoriasis

K. Reich, 2009 .

Efficacy and safety of fumaric acid esters in the long‐term treatment of psoriasis – A retrospective study (FUTURE)

T. Luger, K. Reich, U. Mrowietz, 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.

S. Feldman, J. Silverberg, T. Bieber, 2020, Journal of the American Academy of Dermatology.

Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study.

D. Zillikens, K. Reich, M. Nitschke, 2011, The Journal of allergy and clinical immunology.

Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation.

C. Garbe, K. Reich, U. Lippert, 2001, The Journal of investigative dermatology.

A phase 4, randomized, head‐to‐head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate‐to‐severe plaque psoriasis (CHANGE)

K. Reich, M. Augustin, U. Mrowietz, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5‐year results from the randomized placebo‐controlled TRANSFIGURE study *

B. Elewski, K. Reich, M. Augustin, 2020, The British journal of dermatology.

Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32‐week results from the randomized placebo‐controlled TRANSFIGURE trial

K. Reich, M. Augustin, U. Mrowietz, 2019, The British journal of dermatology.

Secukinumab is superior to fumaric acid esters in treating patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial

M. Sticherling, K. Reich, M. Augustin, 2017, The British journal of dermatology.

Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes

H. Nakagawa, A. Menter, A. Costanzo, 2014, The British journal of dermatology.

Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus

J. Saurat, K. Reich, R. Langley, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

Nail psoriasis in Germany: epidemiology and burden of disease

K. Reich, M. Augustin, C. Blome, 2010, The British journal of dermatology.

Approach to managing patients with nail psoriasis

K. Reich, 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.

F. Nestle, K. Reich, C. Griffiths, 2008, Journal of the American Academy of Dermatology.

A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64‐week multinational randomized phase IV study in 1790 patients (PSO‐TOP)

P. Gisondi, K. Reich, E. D. De Jong, 2017, The British journal of dermatology.

Therapy of psoriasis in childhood and adolescence ‐ a German expert consensus

H. Gollnick, M. Sticherling, K. Reich, 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Australasian College of Dermatologists Abstracts Presented at the 52nd Annual Scientific Meeting 18–21 May 2019 Melbourne Convention and Exhibition Centre Melbourne, Victoria

M. Lebwohl, K. Khosrotehrani, A. Verma, 2019, Australasian Journal of Dermatology.

IXORA-S 1 Ixekizumab provides superior efficacy compared to u stekinumab over 52-weeks of 1 treatment : results from IXORA-S , a phase 3 study 2

K. Reich, C. Griffiths, Kristin Hollister, 2018 .

TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele.

I. König, A. Reis, K. Reich, 2007, Arthritis and rheumatism.

Secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years

A. Armstrong, F. Kolbinger, K. Reich, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

COVID‐19 and implications for dermatological and allergological diseases

T. Buhl, M. Worm, M. Goebeler, 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis.

Vinod K. Sharma, M. Lebwohl, A. Oakley, 2022, JAMA dermatology.

Methotrexate therapy in dermatology

K. Reich, U. Mrowietz, S. Domm, 2012, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest

K. Reich, M. Augustin, U. Mrowietz, 2015, Archives of Dermatological Research.

German psoriasis registry PsoBest: objectives, methodology and baseline data

T. Luger, K. Reich, M. Augustin, 2014, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Interleukin‐17A: a unique pathway in immune‐mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis

B. Kirkham, A. Kavanaugh, K. Reich, 2014, Immunology.

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials

J. Silverberg, T. Bieber, A. Paller, 2020, The British journal of dermatology.

Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

T. Bieber, J. Thyssen, M. Gooderham, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Mouse models of atopic dermatitis: a critical reappraisal

R. Paus, M. Steinhoff, K. Reich, 2020, Experimental dermatology.

Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial.

J. Silverberg, K. Papp, K. Reich, 2019, Journal of Allergy and Clinical Immunology.

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

J. Erickson, T. Luger, M. Ohtsuki, 2016, The New England journal of medicine.

CD40 ligation during dendritic cell maturation reduces cell death and prevents interleukin‐10‐induced regression to macrophage‐like monocytes

H. Haenssle, T. Buhl, K. Reich, 2008, Experimental dermatology.

Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis.

U. Müller-Ladner, R. Gay, S. Gay, 2005, Arthritis and rheumatism.

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.

M. Lebwohl, K. Papp, K. Reich, 2010, Journal of the American Academy of Dermatology.

Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study.

P. Mease, K. Reich, 2009, Journal of the American Academy of Dermatology.

Effects of biologic therapies on the severity of skin symptoms and quality of life in patients with plaque-type psoriasis: a meta-analysis.

K. Reich, C. Griffiths, J. Barker, 2007 .

[The role of biologics into the management of psoriasis: a consensus paper by the Psoriasis Study Group, Arbeitsgemeinschaft Dermatologische Forschung].

M. Sticherling, K. Reich, U. Mrowietz, 2003, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Expression of the T-cell chemoattractant chemokine lymphotactin in Crohn's disease.

H. Radzun, B. Gunawan, K. Reich, 2001, The American journal of pathology.

Rapid quantitation of proinflammatory and chemoattractant cytokine expression in small tissue samples and monocyte-derived dendritic cells: validation of a new real-time RT-PCR technology.

K. Reich, S. Blaschke, V. Blaschke, 2000, Journal of immunological methods.

Rational for statin use in psoriatic patients

A. Pietrzak, K. Reich, J. Szepietowski, 2013, Archives of Dermatological Research.

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)

M. Cork, M. D. de Bruin‐Weller, K. Reich, 2018, The British journal of dermatology.

Transition to ustekinumab in patients with moderate‐to‐severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT)

S. Chimenti, J. Lambert, T. Luger, 2014, The British journal of dermatology.

One‐year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate‐to‐severe plaque psoriasis

S. Chimenti, J. Lambert, T. Luger, 2014, The British journal of dermatology.

Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis

A. Armstrong, J. Silverberg, M. D. de Bruin‐Weller, 2021, American Journal of Clinical Dermatology.

Methods used for indirect comparisons of systemic treatments for psoriasis. A systematic review

K. Reich, M. Augustin, A. Nast, 2022, Skin Health and Disease.

A variant of the CXCL11 gene may influence susceptibility to contact allergy, particularly in polysensitized patients

K. Schäkel, T. Brüning, A. Heratizadeh, 2016, Contact dermatitis.

Genetic diagnostics in inflammatory dermatoses – from insights into pathophysiology to individualized patient management

K. Reich, T. Falk, N. Blödorn-Schlicht, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

European S3‐Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC

P. Gisondi, K. Papp, K. Reich, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis

K. Reich, L. Puig, C. Conrad, 2021, The Journal of dermatological treatment.

Strategies for improving the quality of care in psoriasis with the use of treatment goals – a report on an implementation meeting

K. Kragballe, K. Reich, U. Mrowietz, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

Influence of psoriasis on circulatory system function assessed in echocardiography

A. Pietrzak, K. Reich, J. Mosiewicz, 2015, Archives of Dermatological Research.

Treatment Satisfaction in Psoriasis: Development and Use of the PsoSat Patient Questionnaire in a Cross-Sectional Study

K. Reich, M. Augustin, C. Spehr, 2016, Dermatology.

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations

P. Gisondi, K. Reich, E. D. De Jong, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis

J. Silverberg, K. Peris, T. Bieber, 2020, JAMA dermatology.

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double‐blinded, placebo‐controlled studies (CIMPASI‐1 and CIMPASI‐2)

A. Gottlieb, K. Reich, A. Blauvelt, 2018, Journal of the American Academy of Dermatology.

Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.

K. Reich, H. Villesen, A. Kroker, 2011, Clinical therapeutics.

Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.

J. Silverberg, E. Simpson, K. Reich, 2021, JAMA dermatology.

Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials

M. Lebwohl, K. Reich, A. Blauvelt, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

A. Armstrong, K. Reich, A. Blauvelt, 2019, The Lancet.

Safety of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials

A. Kimball, S. Green, M. Gooderham, 2018, The British journal of dermatology.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate‐to‐severe plaque psoriasis up to 1 year: Results from the CLEAR study

F. Vanaclocha, K. Reich, A. Blauvelt, 2017, Journal of the American Academy of Dermatology.

Health Services Research in Psoriasis – The German Approach

K. Reich, M. Augustin, S. Rustenbach, 2009, Dermatology.

Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial

A. Gottlieb, H. Nakagawa, K. Papp, 2015, The British journal of dermatology.

The hair follicle‐psoriasis axis: Shared regulatory mechanisms and therapeutic targets

R. Paus, K. Reich, T. Ito, 2021, Experimental dermatology.

The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement

W. Lehmacher, C. Seitz, M. Meurer, 2008, Rheumatology.

Allergic Contact Dermatitis and Atopic Eczema

A. Schnuch, W. Uter, K. Reich, 2006 .

Safety of guselkumab in patients with moderate‐to‐severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies

A. Kimball, A. Armstrong, K. Papp, 2019, The British journal of dermatology.

Cytokine gene polymorphisms in atopic dermatitis

A. Ziegler, K. Reich, R. Mössner, 2003, The British journal of dermatology.

Association of allergic contact dermatitis with a promoter polymorphism in the IL16 gene.

I. König, A. Ziegler, A. Schnuch, 2003, The Journal of allergy and clinical immunology.

Treatment goals in psoriasis

K. Reich, U. Mrowietz, 2007, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Use of dose–exposure–response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis

M. Lebwohl, K. Reich, M. Song, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study

P. Gisondi, K. Reich, U. Mrowietz, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.

K. Reich, K. Gordon, Y. Wasfi, 2015, The New England journal of medicine.

Ustekinumab and Marked Clinical Responses in Patients with Moderate to Severe Psoriasis

K. Reich, U. Mrowietz, R. Langley, 2010 .

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

M. Lebwohl, K. Papp, K. Reich, 2008, The Lancet.

Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patients

T. Wienker, A. Reis, K. Reich, 2005, Journal of Medical Genetics.

Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies).

R. Eming, K. Reich, M. Hertl, 2007, Archives of dermatology.

Genotype and phenotype of N‐acetyltransferase 2 (NAT2) polymorphism in patients with contact allergy

J. Geier, P. Koch, D. Becker, 1998, Contact Dermatitis.

Evidence‐based (S3) guidelines for the treatment of psoriasis vulgaris

H. Orzechowski, K. Reich, M. Sebastian, 2007, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Psoriasis and metabolic syndrome in children: current data

J. Roliński, A. Pietrzak, K. Reich, 2017, Clinical and experimental dermatology.

Variations in the genes encoding the peroxisome proliferator-activated receptors α and γ in psoriasis

I. König, A. Ziegler, R. Kaiser, 2004, Archives of Dermatological Research.

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3)

J. Erickson, M. Ohtsuki, K. Papp, 2018, The British journal of dermatology.

Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label OPTIMISE study

K. Reich, J. Szepietowski, J. Szepietowski, 2020, The British journal of dermatology.

Long‐term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease

L. Coates, K. Reich, R. Warren, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method

K. Reich, C. Leonardi, U. Mrowietz, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efﬁcacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

D. Shrom, R. Burge, C. Griffiths, 2020 .

Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach

K. Reich, P. Spuls, A. Nast, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

D. Shrom, L. Ferris, R. Burge, 2020, Dermatology and Therapy.

Efficacy of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28

S. Green, M. Gooderham, K. Papp, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA‐S, a phase 3 study

K. Reich, P. C. van de Kerkhof, C. Griffiths, 2019, Journal of the American Academy of Dermatology.

Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study

A. Menter, E. Edson-Heredia, K. Reich, 2019, The British journal of dermatology.

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis.

S. Ball, K. Reich, A. Blauvelt, 2018, The Journal of investigative dermatology.

An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

J. Niesmann, K. Reich, U. Mrowietz, 2017, The Lancet.

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

A. Kimball, S. Green, K. Papp, 2017, The Lancet.

Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up

M. Lebwohl, K. Reich, Y. Wasfi, 2015, The British journal of dermatology.

Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials

A. Armstrong, K. Papp, K. Reich, 2015, American Journal of Clinical Dermatology.

Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up

B. Strober, M. Lebwohl, C. Griffiths, 2013, The British journal of dermatology.

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo‐controlled trial with a re‐treatment extension

A. Gottlieb, J. Ortonne, P. Mease, 2012, The British journal of dermatology.

In touch with psoriasis: topical treatments and current guidelines

G. Murphy, K. Reich, G. Murphy, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

Variations in the genes encoding the peroxisome proliferator-activated receptors alpha and gamma in psoriasis.

I. König, A. Ziegler, R. Kaiser, 2004, Archives of dermatological research.

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

M. Lebwohl, A. Armstrong, K. Papp, 2021, The Lancet.

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies

A. Armstrong, K. Papp, K. Reich, 2018, American Journal of Clinical Dermatology.

Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.

K. Reich, E. Wu, J. Signorovitch, 2010, Journal of the American Academy of Dermatology.

Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.

A. Gottlieb, M. Bala, A. Menter, 2008, Journal of drugs in dermatology : JDD.

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

M. Lebwohl, A. Armstrong, M. Gooderham, 2019, Dermatology and Therapy.

Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks.

W. Koenig, A. Waisman, V. Mani, 2019, The Journal of investigative dermatology.

Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.

K. Schäkel, T. Zuberbier, T. Bieber, 2011, The Journal of allergy and clinical immunology.

Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

John D. Davis, I. Hussain, S. Forman, 2020 .

Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study.

John D. Davis, I. Hussain, M. D. de Bruin‐Weller, 2020, Journal of the American Academy of Dermatology.

Prospective validation of the “rhino conjunctivitis allergy-control-SCORE©” (RC-ACS©)

K. Reich, Annett Lotzin, I. Zschocke, 2012, Clinical and Translational Allergy.

German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 2: Treatment monitoring and specific clinical or comorbid situations

K. Reich, M. Sebastian, M. Augustin, 2021, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Recommendations for the Long-Term Treatment of Psoriasis with Infliximab: A Dermatology Expert Group Consensus

J. Saurat, S. Chimenti, J. Ortonne, 2008, Dermatology.

Response to fumaric acid esters for plaque type psoriasis in real-world practice is largely independent of patient characteristics at baseline – a multivariable regression analysis from the German Psoriasis Registry PsoBest

K. Reich, M. Augustin, U. Mrowietz, 2022, The Journal of dermatological treatment.

Evidence for a role of Langerhans cell-derived IL-16 in atopic dermatitis.

Ruth Williams, K. Reich, P. Middel, 2002, The Journal of allergy and clinical immunology.

Letter to the Editor in Response to recently published article, ‘Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis’

A. Gottlieb, K. Papp, S. Ball, 2017 .

S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 1 – Systemic treatment

K. Reich, M. Sebastian, M. Augustin, 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 1: Treatment goals and treatment recommendations

K. Reich, M. Sebastian, M. Augustin, 2021, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Definition of treatment goals for moderate to severe psoriasis: a European consensus

C. Griffiths, T. Nijsten, L. Iversen, 2010, Archives of Dermatological Research.

Tumor necrosis factor antagonists in the therapy of psoriasis.

K. Reich, M. Schön, R. Mössner, 2008, Clinics in dermatology.

Efficacy and safety of infliximab vs. methotrexate in patients with moderate‐to‐severe plaque psoriasis: results of an open‐label, active‐controlled, randomized trial (RESTORE1)

J. Ortonne, K. Reich, J. Barker, 2011, The British journal of dermatology.

Treatment of severe psoriasis and psoriatic arthritis with leflunomide

K. Reich, R. Mössner, K. Hummel, 2002, The British journal of dermatology.

Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo‐controlled phase IIa study

K. Reich, C. Griffiths, M. Binks, 2016, The British journal of dermatology.

Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate‐to‐severe plaque psoriasis: results of a randomized, long‐term extension trial (RESTORE2)

K. Reich, J. Barker, G. Wozel, 2013, The British journal of dermatology.

Topical long‐term therapy of psoriasis with vitamin D3 analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice

B. Bonnekoh, K. Reich, M. Augustin, 2014, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Infliximab in the treatment of psoriasis

K. Reich, R. Mössner, 2006 .

Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial

M. Gooderham, K. Reich, L. Kristensen, 2022, Dermatology practical & conceptual.

Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis

K. Reich, M. Augustin, M. Radtke, 2014, The British journal of dermatology.

Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque‐type psoriasis

K. Reich, M. Augustin, R. Mössner, 2009, The British journal of dermatology.

Consistency of Infliximab Response across Subgroups of Patients with Psoriasis: Integrated Results from Randomized Clinical Trials

A. Gottlieb, A. Menter, K. Reich, 2007 .

Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis

S. Chimenti, J. Lambert, T. Luger, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

A. Gottlieb, K. Papp, K. Reich, 2016, The British journal of dermatology.

Long‐term safety profile of ixekizumab in patients with moderate‐to‐severe plaque psoriasis: an integrated analysis from 11 clinical trials

K. Reich, R. Langley, R. Langley, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Five-year maintenance of clinical response and improvements in health-related quality of life in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2

C. Griffiths, K. Reich, P. Foley, 2021 .

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA‐AD™): a clinical outcome measure for the severity of atopic dermatitis

J. Silverberg, A. Paller, J. Thyssen, 2022, British Journal of Dermatology.

Treatment of psoriasis with interleukin-10.

C. Garbe, K. Reich, C. Neumann, 1998, The Journal of investigative dermatology.

Cyclosporine therapy in dermatology

K. Reich, M. Sebastian, U. Mrowietz, 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

The German National Program on Psoriasis Health Care 2005–2015: results and experiences

A. Enk, K. Reich, M. Augustin, 2016, Archives of Dermatological Research.

Generalized pustular psoriasis: overview of the status quo and results of a panel discussion

K. Schäkel, G. Kokolakis, M. Sticherling, 2022, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Maintenance of response in moderate‐to‐severe psoriasis after withdrawal of the interleukin (IL)‐17A and IL‐17F nanobody sonelokimab: is there a role for IL‐17F in disease reoccurrence?

K. Reich, E. Cullen, M. Weinberg, 2022, The British journal of dermatology.

A multicentre open‐label study of apremilast in palmoplantar pustulosis (APLANTUS)

K. Reich, R. Sabat, R. Mössner, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study

K. Schäkel, K. Reich, U. Mrowietz, 2021, Dermatology and Therapy.

Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis and non‐pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER‐1, UNCOVER‐2 and UNCOVER‐3)

D. Shrom, A. Menter, K. Reich, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks

M. Lebwohl, L. Iversen, M. Ohtsuki, 2019, The British journal of dermatology.

Is Complete Skin Clearance in Psoriasis the Answer ?

L. Iversen, K. Reich, H. Bachelez, 2018 .

Interleukin-23 in Psoriasis: Integrating New Therapies in the Current Treatment Landscape

G. Girolomoni, K. Reich, A. Blauvelt, 2018 .

Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE‐2 and ‐3

K. Reich, R. Warren, C. Paul, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Advancing the Treatment of Psoriatic Arthritis: Focus on the IL-23 Pathway

L. Coates, G. Schett, K. Reich, 2020 .

What is the Best Target for Psoriasis : IL-23 Versus IL-17 A ? Doctor

K. Reich, A. Blauvelt, R. Warren, 2018 .

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).

S. Chimenti, K. Papp, K. Reich, 2015, Journal of the American Academy of Dermatology.

Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study

A. Armstrong, K. Reich, Y. You, 2021, The Journal of dermatological treatment.

Clinical meaningfulness of complete skin clearance in psoriasis.

B. Strober, M. Lebwohl, K. Papp, 2016, Journal of the American Academy of Dermatology.

Immunoglobulin E-Selective Immunoadsorption Reduces Peripheral and Skin-Bound Immunoglobulin E and Modulates Cutaneous IL-13 Expression in Severe Atopic Dermatitis.

J. Schröder, K. Reich, T. Falk, 2019, The Journal of investigative dermatology.

IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study

K. Papp, K. Reich, M. Weinberg, 2021, The Lancet.

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)

M. Gooderham, A. Bewley, K. Reich, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

Psoriasis--new insights into pathogenesis and treatment.

K. Reich, U. Mrowietz, 2009, Deutsches Arzteblatt international.

Calcium spirulan derived from Spirulina platensis inhibits herpes simplex virus 1 attachment to human keratinocytes and protects against herpes labialis.

W. Handke, K. Reich, Patrick Günther, 2016, The Journal of allergy and clinical immunology.

Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate‐to‐severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo‐controlled, phase III clinical trial (BREEZE‐AD4) *

T. Bieber, K. Reich, M. Augustin, 2022, The British journal of dermatology.

Engagement of the FcεRI Stimulates the Production of IL-16 in Langerhans Cell-Like Dendritic Cells1 2

H. Tilg, A. Kaser, K. Reich, 2001, The Journal of Immunology.

Topology of psoriasis in routine care: results from high‐resolution analysis of 2009 patients

K. Reich, M. Augustin, U. Mrowietz, 2019, The British journal of dermatology.

Exposure‐Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis

N. Vélez de Mendizábal, K. Reich, S. Friedrich, 2018, Journal of clinical pharmacology.

Cost‐of‐illness of psoriasis – results of a German cross‐sectional study

K. Reich, M. Augustin, K. Strömer, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Impact of ixekizumab treatment on skin‐related personal relationship difficulties in moderate‐to‐severe psoriasis patients: 12‐week results from two Phase 3 trials

M. Lebwohl, K. Reich, R. Warren, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate‐to‐severe plaque psoriasis

A. Armstrong, K. Reich, A. Blauvelt, 2017, The British journal of dermatology.

Title : Cost-of-illness of psoriasis-results of a German cross-sectional study Running head : Cost-of-illness of psoriasis in Germany

K. Reich, M. Augustin, K. Strömer, 2017 .

Patient-relevant treatment goals in psoriasis

K. Reich, M. Augustin, C. Blome, 2016, Archives of Dermatological Research.

Transcriptomic Analysis of Blaschko-Linear Psoriasis Reveals Shared and Distinct Features with Psoriasis Vulgaris.

J. McGrath, C. Ainali, K. Reich, 2021, The Journal of investigative dermatology.

More on PML in Patients Treated with Dimethyl Fumarate.

M. Lebwohl, H. Hartung, K. Reich, 2016, The New England journal of medicine.

A close look at autoimmune muscle disorders: association of Lambert–Eaton myasthenic syndrome with dermatomyositis

W. Paulus, K. Reich, R. Mössner, 2004, Scandinavian journal of rheumatology.

Interleukin 16 expression and phenotype of interleukin 16 producing cells in Crohn's disease

M. Korabiowska, H. Radzun, J. Herms, 2001, Gut.

Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis

K. Reich, P. C. van de Kerkhof, J. Barker, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials

M. Ohtsuki, K. Reich, R. Romiti, 2017, Journal of the American Academy of Dermatology.

Granulocyte colony‐stimulating‐factor‐induced psoriasiform dermatitis resembles psoriasis with regard to abnormal cytokine expression and epidermal activation

K. Reich, R. Mössner, C. Neumann, 2004, Experimental dermatology.

The maturation‐dependent production of interleukin‐16 is impaired in monocyte‐derived dendritic cells from atopic dermatitis patients but is restored by inflammatory cytokines TNF‐α and IL‐1β

K. Reich, P. Middel, V. Blaschke, 2004, Experimental dermatology.

Expression of the CD4+ cell-specific chemoattractant interleukin-16 in mycosis fungoides.

K. Reich, P. Middel, V. Blaschke, 1999, The Journal of investigative dermatology.

Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial *

K. Reich, M. Augustin, G. Bruin, 2022, The British journal of dermatology.

Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials

K. Reich, G. Stingl, C. Paul, 2022, Acta dermato-venereologica.

IL-23 Inhibition: From Pathophysiological Jungle to Clinical Clearance

K. Reich, B. Kirby, Richard B. Warren, 2019 .

Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials

K. Reich, K. Gordon, Y. Poulin, 2020, The Journal of dermatological treatment.

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies†

M. Gooderham, K. Papp, K. Reich, 2019, The British journal of dermatology.

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab†

K. Papp, K. Reich, A. Blauvelt, 2019, The British journal of dermatology.

Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance

K. Reich, P. Foley, K. Gordon, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Consistent responses with guselkumab treatment in Asian and non‐Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2

K. Reich, K. Gordon, S. Youn, 2019, The Journal of dermatology.

Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study.

A. Armstrong, E. Muñoz-Elías, K. Reich, 2019, The Journal of investigative dermatology.

Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis––a multinational cross-sectional study

J. Schmitt, K. Kragballe, K. Reich, 2013, Archives of Dermatological Research.

Glyceryl (mono)caprylate – a new contact allergen

K. Reich, K. Breuer, V. Steinkraus, 2013, Contact dermatitis.

Use of fumaric acid esters in psoriasis.

A. Bõer, K. Reich, A. Roll, 2007, Indian journal of dermatology, venereology and leprology.

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study

R. Petric, M. Gooderham, A. Bewley, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study *

J. Früh, M. Sticherling, K. Reich, 2020, The British journal of dermatology.

Continued treatment with secukinumab is associated with high retention or regain of response

M. Lebwohl, K. Reich, M. Augustin, 2019, The British journal of dermatology.

Evaluation of Quality of Care and Guideline-Compliant Treatment in Psoriasis

K. Reich, M. Augustin, C. Blome, 2009, Dermatology.

An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals

K. Kragballe, K. Reich, C. Griffiths, 2013, The British journal of dermatology.

Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO

J. Roemmler-Zehrer, K. Reich, N. Magnolo, 2021, Dermatology and Therapy.

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study

F. Vanaclocha, K. Reich, A. Blauvelt, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

In touch with psoriasis: a patient‐centred approach to therapy

K. Reich, R. Langley, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

Erratum

K. Reich, 2011, Dermatology.

Secukinumab in plaque psoriasis--results of two phase 3 trials.

B. Elewski, M. Lebwohl, H. Nakagawa, 2014, The New England journal of medicine.

Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL)

W. Hiddemann, F. Strutz, K. Reich, 1997, Annals of Hematology.

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study

M. Lebwohl, A. Menter, K. Reich, 2017, American Journal of Clinical Dermatology.

What is new in topical therapy for psoriasis?

A. Bewley, K. Reich, A. Bewley, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double‐blind, controlled trial

L. Vaillant, S. Segaert, K. Reich, 2009, The British journal of dermatology.

Clinical improvement of HIV-associated psoriasis parallels a reduction of HIV viral load induced by effective antiretroviral therapy.

G. Ramadori, K. Reich, H. Schwörer, 1999, AIDS.

Treatment of pyoderma gangrenosum with topical tacrolimus

K. Reich, C. Neumann, C. Vente, 1998 .

Epidemiology and comorbidity of psoriasis in children

G Glaeske, M Augustin, K. Reich, 2010, The British journal of dermatology.

Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0·05% combined with ketoconazole shampoo 2%: a randomized, controlled study

J. Ortonne, A. Nikkels, K. Reich, 2011, The British journal of dermatology.

Extensive hyperpigmentation of the face in a Filipina

K. Reich, J. Pirrone, Jasmin Broyer, 2017, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.

M. Lebwohl, K. Papp, K. Reich, 2012, Journal of drugs in dermatology : JDD.

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

F. Nestle, J. Ortonne, K. Papp, 2005, The Lancet.

Secukinumab improves hand, foot and nail lesions in moderate‐to‐severe plaque psoriasis: subanalysis of a randomized, double‐blind, placebo‐controlled, regimen‐finding phase 2 trial

A. Gottlieb, K. Reich, U. Mrowietz, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Nail psoriasis as a severity indicator: results from the PsoReal study

K. Reich, M. Augustin, M. Radtke, 2010, Patient related outcome measures.

Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial

J. Saurat, J. Ortonne, K. Papp, 2010, Dermatology.

["TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept].

A. Heiligenhaus, U. Müller-Ladner, K. Reich, 2009, Deutsche medizinische Wochenschrift.

Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ)

K. Reich, U. Mrowietz, Annett Lotzin, 2014, Archives of Dermatological Research.

Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey

M. Lebwohl, G. Girolomoni, A. Kavanaugh, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Non‐adherence and measures to improve adherence in the topical treatment of psoriasis

K. Reich, U. Mrowietz, I. Zschocke, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP)

K. Reich, U. Mrowietz, I. Zschocke, 2014, Archives of Dermatological Research.

Association analysis of IL19, IL20 and IL24 genes in palmoplantar pustulosis

S. Kõks, K. Reich, K. Kingo, 2007, The British journal of dermatology.

Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany

K. Reich, M. Augustin, M. Radtke, 2008, Dermatology.

Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.

M. Lebwohl, G. Girolomoni, A. Kavanaugh, 2014, Journal of the American Academy of Dermatology.

The concept of psoriasis as a systemic inflammation: implications for disease management

K. Reich, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

Contact sensitization to essential oils: IVDK data of the years 2010–2019

J. Geier, W. Uter, K. Reich, 2022, Contact dermatitis.

Expert recommendations: the use of the fixed combination calcipotriol and betamethasone dipropionate gel for the topical treatment of psoriasis

J. Lambert, G. Girolomoni, A. Bewley, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Clinical use of dimethyl fumarate in moderate‐to‐severe plaque‐type psoriasis: a European expert consensus

L. Naldi, L. Iversen, K. Reich, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Quality of psoriasis care in Germany – results of the national study PsoHealth 2007

K. Reich, M. Augustin, M. Radtke, 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma.

L. Füzesi, K. Reich, S. Schinner, 2002, The Journal of investigative dermatology.

N‐acetyltransferase 1 and 2 polymorphisms in para‐substituted arylamine‐induced contact allergy

A. Schnuch, K. Reich, E. Hallier, 2000, The British journal of dermatology.

Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double‐blind, placebo‐ and active comparator–controlled VOYA

A. Armstrong, K. Reich, P. Foley, 2017, Journal of the American Academy of Dermatology.

Digestive system in psoriasis: an update

A. Pietrzak, K. Reich, D. Krasowska, 2017, Archives of Dermatological Research.

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies

M. Lebwohl, C. Griffiths, K. Reich, 2011, The British journal of dermatology.

Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey

K. Reich, M. Augustin, C. Blome, 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

Early detection of comorbidity in psoriasis: recommendations of the National Conference on Healthcare in Psoriasis

J. Wohlrab, K. Reich, M. Härter, 2015, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis

B. Strober, K. Papp, K. Reich, 2011, American journal of clinical dermatology.

[Psoriasis-associated keratitis: case report].

K. Reich, V. G. Herbert, F. Filev, 2014, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.

F. Vanaclocha, K. Reich, A. Blauvelt, 2015, Journal of the American Academy of Dermatology.

Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study

J. Saurat, E. Sasso, K. Reich, 2011, The British journal of dermatology.

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study

A. Gottlieb, I. McInnes, K. Reich, 2021, The British journal of dermatology.

Systemic treatment with corticosteroids in psoriasis–health care provision far beyond the S3‐guidelines

K. Reich, M. Augustin, G. Glaeske, 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[15 years of fumaderm: fumaric acid esters for the systemic treatment of moderately severe and severe psoriasis vulgaris].

K. Reich, U. Mrowietz, M. Rostami-Yazdi, 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Silica gel is as effective as acyclovir cream in patients with recurrent herpes labialis: Results of a randomized, open‐label trial

K. Reich, A. Zielke, I. Zschocke, 2008, The Journal of dermatological treatment.

Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany.

I. Schaefer, K. Reich, M. Augustin, 2010, Acta dermato-venereologica.

Variations in the peroxisome proliferator-activated receptor-γ gene and melanoma risk

C. Berking, I. König, A. Ziegler, 2007 .

Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset.

I. König, A. Ziegler, K. Reich, 2002, The Journal of investigative dermatology.

Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis.

M. Müller, K. Reich, Michael Müller, 1999, The Journal of investigative dermatology.

Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomized phase II study

K. Reich, N. Mehta, O. Graff, 2016, The British journal of dermatology.

An open‐label study assessing the safety and efficacy of alitretinoin in patients with severe chronic hand eczema unresponsive to topical corticosteroids

K. Reich, R. Bissonnette, T. Dirschka, 2011, Clinical and experimental dermatology.

Replication of LCE3C-LCE3B CNV as a risk factor for psoriasis and analysis of interaction with other genetic risk factors.

Xavier Estivill, André Reis, Tim Becker, 2010, The Journal of investigative dermatology.

Who is really in control of skin immunity under physiological circumstances – lymphocytes, dendritic cells or keratinocytes?

A. Kerstan, R. Paus, K. Reich, 2006, Experimental dermatology.

Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis

David M. Phillippo, K. Reich, K. Fahrbach, 2021, Dermatology and Therapy.

Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis

B. Strober, M. Lebwohl, A. Menter, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)

M. Lebwohl, F. Kerdel, K. Reich, 2017, The Journal of dermatological treatment.

First "Real-World" Insights on Apremilast Treatment for Patients with Plaque Psoriasis from the LAPIS-PSO Study: An Interim Analysis

K. Reich, B. Korge, Stefanie Bomas, 2017 .

Efficacy and safety of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER‐3)

L. Iversen, M. Gooderham, S. Ball, 2017, Journal of the American Academy of Dermatology.

Outcome assessment and treatment goals

A. Finlay, K. Reich, 2008 .

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials

M. Gooderham, K. Papp, K. Reich, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

K. Reich, M. Augustin, U. Mrowietz, 2020, PloS one.

How do regional factors influence psoriasis patient care in Germany?

K. Reich, M. Augustin, C. Blome, 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab

K. Reich, C. Griffiths, 2008, Archives of Dermatological Research.

Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study

K. Reich, M. Augustin, J. Prinz, 2006, Dermatology.

Patient-relevant needs and treatment goals in nail psoriasis

H. Nakagawa, A. Menter, A. Costanzo, 2016, Quality of Life Research.

Costs and quality of life in patients with moderate to severe plaque‐type psoriasis in Germany: A multi‐center study

K. Reich, M. Augustin, O. Schöffski, 2007, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial†

Kelly N. Taylor, Constance M. Brown, B. Elewski, 2019, The British journal of dermatology.

Rapid improvements in health‐related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER‐2 and UNCOVER‐3

R. Burge, M. Gooderham, K. Reich, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Genetic factors in contact allergy—review and future goals

A. Schnuch, W. Uter, K. Reich, 2011, Contact dermatitis.

Complete remission of severe chronic recurrent angioedema of unknown cause with omalizumab

K. Reich, K. Breuer, V. Steinkraus, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study)

T. Gambichler, K. Reich, I. Zschocke, 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC

P. Gisondi, K. Papp, K. Reich, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions – a retrospective evaluation (FACTS)

K. Reich, M. Augustin, D. Thaçi, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.

A. Kimball, V. Ho, K. Papp, 2012, Journal of the American Academy of Dermatology.

A new treatment option for paediatric psoriasis

K. Reich, 2020, The British journal of dermatology.

Drug supply for children with psoriasis in Germany

K. Reich, M. Augustin, G. Glaeske, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Efficacy and safety of fumaric acid esters in combination with phototherapy in patients with moderate‐to‐severe plaque psoriasis (FAST)

K. Reich, P. Weisenseel, I. Zschocke, 2017, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[S3-Guidelines for the therapy of psoriasis vulgaris].

H. Orzechowski, K. Reich, M. Sebastian, 2006, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

No association of vitamin D metabolism-related polymorphisms and melanoma risk as well as melanoma prognosis: a case–control study

C. Berking, I. König, J. Kruppa, 2012, Archives of Dermatological Research.

Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis

Martin M. Schumacher, F. Kolbinger, K. Papp, 2015, Experimental dermatology.

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials

A. Deodhar, I. McInnes, K. Reich, 2019, Annals of the rheumatic diseases.

Long‐term follow‐up of photodynamic therapy with a self‐adhesive 5‐aminolaevulinic acid patch: 12 months data

A. Hauschild, A. Moor, U. Reinhold, 2010, The British journal of dermatology.

Optimization of photodynamic therapy with a novel self‐adhesive 5‐aminolaevulinic acid patch: results of two randomized controlled phase III studies

A. Hauschild, A. Moor, U. Reinhold, 2009, The British journal of dermatology.

Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis

C. Berking, H. Hönigsmann, U. Reinhold, 2013, The British journal of dermatology.

Photodynamic therapy with BF‐200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer‐blind phase III study in comparison with a registered methyl‐5‐aminolaevulinate cream and placebo

C. Berking, H. Hönigsmann, U. Reinhold, 2012, The British journal of dermatology.

Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanoma

C. Berking, I. König, A. Ziegler, 2006, Archives of Dermatological Research.

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

A. Gottlieb, M. Lebwohl, A. Deodhar, 2022, Acta dermato-venereologica.

Erratum to: Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study

M. Lebwohl, A. Menter, K. Reich, 2017, American Journal of Clinical Dermatology.

Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials.

M. Ohtsuki, M. Gooderham, S. Ball, 2018, Journal of drugs in dermatology : JDD.

Comparison of ixekizumab with ustekinumab in moderate‐to‐severe psoriasis: 24‐week results from IXORA‐S, a phase III study

L. French, K. Reich, G. Micali, 2017, The British journal of dermatology.

Short‐ and long‐term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data

B. Strober, M. Lebwohl, L. Ferris, 2017, Journal of the American Academy of Dermatology.

The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate‐to‐severe plaque psoriasis

K. Reich, L. Mallbris, L. Puig, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti‐tumour necrosis factor agents: subanalysis of BELIEVE

S. Chimenti, J. Ortonne, K. Reich, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate‐to‐severe plaque psoriasis naïve to systemic treatment

K. Reich, M. Augustin, U. Mrowietz, 2020, The British journal of dermatology.

A consensus report on appropriate treatment optimization and transitioning in the management of moderate‐to‐severe plaque psoriasis

J. Schmitt, K. Kragballe, K. Reich, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis.

K. Reich, J. Signorovitch, Fareen Hassan, 2023, Journal of dermatological treatment (Print).

Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results.

K. Reich, R. Langley, C. Papavassilis, 2017, Journal of Drugs in Dermatology.

Use of fumaric acid esters in psoriasis Use of fumaric acid esters in psoriasis

K. Reich, A. Böer, A. Roll, 2007 .

Upadacitinib plus topical corticosteroids in atopic dermatitis: week-52 AD Up study results.

J. Silverberg, T. Bieber, A. Costanzo, 2021, The Journal of allergy and clinical immunology.

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

J. Silverberg, T. Bieber, K. Reich, 2021, The Lancet.

Bimekizumab versus Secukinumab in Plaque Psoriasis.

B. Strober, M. Lebwohl, M. Gooderham, 2021, The New England journal of medicine.

Bimekizumab versus Adalimumab in Plaque Psoriasis.

A. Armstrong, K. Papp, K. Reich, 2021, The New England journal of medicine.

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

K. Reich, P. Foley, K. Gordon, 2021, The Lancet.

A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment

K. Reich, M. Augustin, U. Mrowietz, 2019, The British journal of dermatology.

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3)

J. Erickson, K. Papp, S. Ball, 2018 .

A European subset analysis from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country‐specific features: results from psoriasis patients in Spain

G. Girolomoni, K. Reich, P. V. D. van de Kerkhof, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data

A. Deodhar, P. Mease, I. McInnes, 2019, Arthritis Research & Therapy.

Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE‐2 and AMAGINE‐3

K. Reich, R. Warren, L. Puig, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Maintenance of clinical response and consistent safety profile with up to three years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials.

A. Kimball, A. Armstrong, K. Papp, 2019, Journal of the American Academy of Dermatology.

Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.

I. Hampele, K. Reich, J. Szepietowski, 2022, The British journal of dermatology.

Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2 *

A. Armstrong, C. Griffiths, K. Reich, 2021, The British journal of dermatology.

Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) *

K. Reich, P. Foley, R. Warren, 2021, The British journal of dermatology.

Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study

A. Armstrong, K. Reich, P. Foley, 2020, American Journal of Clinical Dermatology.

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate‐to‐severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO‐BIO‐REAL)

G. Pellacani, A. Bewley, C. De Simone, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials

B. Strober, M. Lebwohl, K. Papp, 2021 .

Zeitmanagement und Lebensqualität nach Umstellung einer topischen und/oder Fototherapie auf Fumar-säureester bei Patienten mit Psoriasis Time Management and Quality of Life After Change of Therapy from Topical Treatment and/or Phototherapy to Fumaderm ® in Patients with Psoriasis

K. Reich, C. Kahl, M. Neureither, 2011 .

Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice

L. French, P. Itin, K. Reich, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Gene expression based molecular test as diagnostic aid for the differential diagnosis of psoriasis and eczema in formalin fixed and paraffin embedded tissue, microbiopsies and tape strips.

F. Fischer, M. Menden, T. Biedermann, 2023, The Journal of investigative dermatology.

Infliximab produces a sustained and significant improvement in psoriasis over 50 weeks of continuous therapy.

F. Nestle, J. Ortonne, K. Papp, 2005 .

Association analysis of IL20RA and IL20RB genes in psoriasis

S. Kõks, K. Reich, K. Kingo, 2008, Genes and Immunity.

Once-Weekly Administration of Etanercept 50 mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis

P. V. D. van de Kerkhof, S. Segaert, K. Reich, 2009, Dermatology.

A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes

Andreas Ziegler, Victor Siskind, Marianne Berwick, 2009, International journal of cancer.

Development and Validation of a Melanoma Risk Score Based on Pooled Data from 16 Case–Control Studies

Tim K. Lee, A. Ziegler, J. Barrett, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Development and Validation of a Melanoma Risk Score Based on PooledData from 16 Case – Control Studies

Tim K. Lee, A. Ziegler, J. Barrett, 2015 .

Molecular diagnostics in dermatology: An online survey to study usage, obstacles and requirements in Germany

T. Biedermann, A. Zink, K. Reich, 2021, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

A. Deodhar, P. Mease, I. McInnes, 2019, Arthritis Research & Therapy.

Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a case-control study.

Sikandar G. Khan, C. Berking, I. König, 2005, Carcinogenesis.

No association between three xeroderma pigmentosum group C and one group G gene polymorphisms and risk of cutaneous melanoma

Sikandar G. Khan, I. König, A. Ziegler, 2005, European Journal of Human Genetics.

Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case–control study

C. Berking, A. Ziegler, N. Schoof, 2009, Genes and Immunity.

Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis.

A. Reis, K. Reich, J. Lascorz, 2009, The Journal of investigative dermatology.

PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

K. Reich, M. Augustin, S. Rustenbach, 1970 .

Measuring Patient Needs and Benefits in Dermatology using the Patient Benefit Index 2.0: A Validation Study.

K. Reich, M. Augustin, C. Blome, 2019, Acta dermato-venereologica.

Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials

J. Silverberg, J. Thyssen, E. Simpson, 2020, The Journal of dermatological treatment.

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate‐to‐severe psoriasis: a randomized controlled trial

F. Nestle, J. Ortonne, K. Papp, 2006, The British journal of dermatology.

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

J. Thyssen, H. Valdez, M. Dibonaventura, 2022, The Lancet.

Evidence‐based (S3) guideline for the treatment of psoriasis vulgaris – Update: “Therapeutic options” and “Efalizumab”

K. Reich, M. Sebastian, M. Augustin, 2010 .

Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab".

K. Reich, M. Sebastian, M. Augustin, 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

SAT0287 Long-Term Safety Of Ustekinumab: 5 Years of Follow-Up from the Psoriasis Clinical Development Program Including Patients with Psoriatic Arthritis

B. Strober, M. Lebwohl, K. Papp, 2013 .

Differential Changes in Inflammatory Mononuclear Phagocyte and T Cell Profiles within Psoriatic Skin during Treatment with Guselkumab versus Secukinumab.

E. Muñoz-Elías, K. Reich, A. Blauvelt, 2021, The Journal of investigative dermatology.

Treatment adherence: a hurdle for real‐life effectiveness in psoriasis?

K. Reich, E. Daudén, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)

A. Gottlieb, K. Reich, K. Gordon, 2020, The British journal of dermatology.

Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.

K. Reich, C. Griffiths, J. Barker, 2008, Current medical research and opinion.

Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care

K. Reich, M. Augustin, U. Mrowietz, 2020, European Journal of Dermatology.

Reaching complete or near‐complete resolution of psoriasis: benefit and risk considerations

M. Lebwohl, C. Griffiths, E. Edson-Heredia, 2017, The British journal of dermatology.

[Paradoxical skin reactions under therapy with TNF-alpha antagonists].

K. Reich, P. Weisenseel, 2013, Zeitschrift für Rheumatologie (Print).

Neutrophilic urticarial dermatosis (NUD) indicating Cryopyrin‐associated periodic syndrome associated with a novel mutation of the NLRP3 gene

K. Reich, K. Ahmadi-Simab, A. Böer‐Auer, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis.

K. Reich, P. Weisenseel, M. Meier, 2016, The Journal of allergy and clinical immunology.

The value of subcutaneous vs. oral methotrexate: real‐world data from the German psoriasis registry PsoBest

K. Reich, M. Augustin, C. Sorbe, 2020, The British journal of dermatology.

National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines

K. Kragballe, K. Reich, L. Puig, 2013, Archives of Dermatological Research.

Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)

G. Pellacani, A. Bewley, C. De Simone, 2020, Dermatology and Therapy.

Characterisation of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1

A. Magener, T. Wienker, T. Becker, 2009, Journal of Medical Genetics.

Quality of psoriasis care in Germany: results of the national health care study “PsoHealth3”

K. Reich, M. Augustin, U. Mrowietz, 2016, Archives of Dermatological Research.

[Infliximab. Role in the treatment of psoriasis].

K. Reich, R. Mössner, 2005, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)

K. Schäkel, K. Asadullah, E. Muñoz-Elías, 2021, BMJ Open.

15280 Characterization of super responders to guselkumab treatment in moderate to severe psoriasis: Results from the VOYAGE 1 and 2 clinical trials

B. Strober, K. Reich, P. Foley, 2020 .

Homozygous gene deletions of the glutathione S-transferases M1 and T1 are associated with thimerosal sensitization

P. Koch, W. Aberer, A. Schnuch, 2000, International archives of occupational and environmental health.

Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis.

M. Lebwohl, A. Pink, H. Valdez, 2022, Journal of Allergy and Clinical Immunology: In Practice.

Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey

M. Lebwohl, P. Gisondi, K. Reich, 2021, Dermatology and Therapy.

Correlation of Physician-Assessed Psoriasis Area and Severity Index Scores With Patient-Reported Psoriasis Symptoms and Signs Diary Scores Among Patients With Moderate-to-Severe Psoriasis: Results From VOYAGE 1 and VOYAGE 2 Studies

K. Reich, Chenglong Han, K. Gordon, 2019, Journal of Psoriasis and Psoriatic Arthritis.

Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis

K. Reich, C. Griffiths, J. Barker, 2008 .

Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long‐term psoriasis management

K. Reich, M. Augustin, U. Mrowietz, 2018, The British journal of dermatology.

Quality of psoriasis care in Germany – results from the nationwide health care studies PsoHealth 2004‐2017

N. Mohr, K. Reich, M. Augustin, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis.

A. Kimball, D. Rader, N. Mehta, 2012, Journal of the American Academy of Dermatology.

Time to relapse after tildrakizumab withdrawal in patients with moderate‐to‐severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial

M. Lebwohl, K. Reich, J. Szepietowski, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment

K. Reich, R. Sabat, K. Ghoreschi, 2023, International journal of molecular sciences.

Alefacept in Psoriatic Arthritis Study Group. Alefacept with methotrexate for treatment of psoriatic arthritis: Open-label extension of a randomized, doubleblind, placebo-controlled study

P. Mease, K. Reich, 2009 .

Network meta‐analyses in psoriasis: overview and critical discussion

K. Reich, M. Augustin, M. V. Valencia López, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Nail Outcome Improvements with Certolizumab Pegol in Moderate to Severe Plaque Psoriasis: Results from Phase 3 Trials

A. Gottlieb, K. Reich, Y. Poulin, 2019, SKIN The Journal of Cutaneous Medicine.

Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial

A. Gottlieb, M. Lebwohl, K. Reich, 2021 .

Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)

K. Papp, K. Reich, A. Blauvelt, 2021 .

S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 2 – Special patient populations and treatment situations

K. Reich, M. Sebastian, M. Augustin, 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Expression of activation-induced, T cell-derived, and chemokine-related cytokine/lymphotactin and its functional role in rheumatoid arthritis.

Brigitte G Dorner, Sabine Blaschke, Gerhard A Müller, 2003, Arthritis and rheumatism.

Association of sex and systemic therapy treatment outcomes in psoriasis: a two‐country, multicentre, prospective, noninterventional registry study *

L. French, K. Reich, U. Mrowietz, 2021, The British journal of dermatology.

Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis.

K. Reich, 2012, The New England journal of medicine.

Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.

K. Reich, A. Blauvelt, K. Kingo, 2019, Journal of the American Academy of Dermatology.

Engagement of the Fc epsilon RI stimulates the production of IL-16 in Langerhans cell-like dendritic cells.

H. Tilg, A. Kaser, K. Reich, 2001, Journal of immunology.

Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab.

R. Burge, M. Gooderham, K. Reich, 2022, Journal of drugs in dermatology : JDD.

Case reports of PML in patients treated for psoriasis.

K. Reich, U. Mrowietz, 2013, The New England journal of medicine.

Evaluation of adherence predictors for the treatment of moderate to severe psoriasis with biologics: the importance of physician–patient interaction and communication

K. Reich, I. Zschocke, C. Ortland, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Which PASI Outcome Is Most Relevant to the Patients in Real-World Care?

K. Reich, M. Augustin, S. Rustenbach, 2021, Life.

What is psoriasis? – Perception and assessment of psoriasis among the German population

A. Enk, K. Reich, M. Augustin, 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Dear‐Doctor‐Letter Fumaderm® – What are the facts?

K. Reich, U. Mrowietz, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Giant Primary Melanoma With No Apparent Metastases: A Report of 2 Cases

K. Reich, G. Glaeske, E. Christophers, 2017 .

Treatment goals in psoriasis routine care

K. Reich, M. Augustin, C. Spehr, 2015, Archives of Dermatological Research.

Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional Study.

L. French, P. Itin, K. Reich, 2019, Acta dermato-venereologica.

Psoriasis inversa

K. Reich, P. Weisenseel, 2015, Der Hautarzt.

Psoriasis inversa

K. Reich, P. Weisenseel, 2015, coloproctology.

An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study

M. Furue, E. Simpson, K. Reich, 2022, The Lancet.

The interpretation of long‐term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials

K. Reich, R. Langley, R. Langley, 2013 .

Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: Results from PHOENIX 2

K. Reich, M. Augustin, L. Guenther, 2011, The Journal of dermatological treatment.

Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.

M. Bala, F. Nestle, K. Reich, 2007, EJD. European journal of dermatology.

Keynote lecture: psoriasis update

K. Reich, 2008 .

Secukinumab re‐initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis

K. Reich, J. Szepietowski, A. Blauvelt, 2017, The British journal of dermatology.

Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris.

I. König, K. Reich, K. Kingo, 2005, The Journal of investigative dermatology.

Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.

K. Reich, Rotraut Mossner, 2009, Current problems in dermatology.

Secukinumab versus guselkumab in the complete resolution of ustekinumab‐resistant psoriatic plaques: The ARROW study

F. Kolbinger, K. Reich, R. Langley, 2023, Experimental dermatology.

Ulcerative keratitis in psoriasis: a rare variant of psoriatic ocular inflammatory disease

K. Reich, V. Gruben, V. G. Herbert, 2014, British Journal of Dermatology.

Measuring patient‐relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10‐item short form

K. Reich, M. Augustin, C. Blome, 2022, The British journal of dermatology.

M. Cork, K. Reich, L. Eckert, 2018 .

Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways

J. Niesmann, K. Reich, U. Mrowietz, 2019, The British journal of dermatology.

Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis

S. Feldman, V. Strand, R. Burge, 2019, Quality of Life Research.

FRI0445 Tildrakizumab Treatment Improved Measures of Psoriatic Arthritis in Adults with Chronic Plaque Psoriasis

K. Papp, K. Reich, R. Langley, 2016 .

Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.

J. Silverberg, E. Simpson, K. Reich, 2022, The British journal of dermatology.

15057 Safety of baricitinib in patients with atopic dermatitis: Results of pooled data from two phase 3 monotherapy randomized, double-blind, placebo-controlled 16-week trials (BREEZE-AD1 and BREEZE-AD2)

J. Silverberg, A. Paller, A. Costanzo, 2020 .

Tepilamide Fumarate (PPC-06) Extended Release Tablets in Patients with Moderate-to-Severe Plaque Psoriasis: Safety and Efficacy Results from the Randomized, Double-blind, Placebo-controlled AFFIRM Study.

Srinivas H Shenoy, M. Lebwohl, K. Reich, 2022, The Journal of clinical and aesthetic dermatology.

Further association analysis of chr 6q22-24 suggests a role of IL-20RA polymorphisms in psoriasis.

S. Kõks, K. Reich, K. Kingo, 2010, Journal of dermatological science.

Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials

J. Silverberg, J. Thyssen, G. Girolomoni, 2022, The British journal of dermatology.

33298 Long-term safety and efficacy of tralokinumab in more than 1400 moderate-to-severe atopic dermatitis patients treated for up to 42 months: An interim analysis of ECZTEND

A. Costanzo, M. Tauber, E. Simpson, 2022, Journal of the American Academy of Dermatology.

Long-term 2-Year Safety and Efficacy of Tralokinumab in Adults with Moderate-to-severe Atopic Dermatitis: Interim Analysis of the ECZTEND Open-label Extension Trial.

K. Peris, A. Pink, E. Simpson, 2022, Journal of the American Academy of Dermatology.

Variations in the peroxisome proliferator-activated receptor-gamma gene and melanoma risk.

C. Berking, I. König, A. Ziegler, 2007, Cancer letters.

Latest Highlights from Guselkumab in Psoriasis from EADV 2019

E. Muñoz-Elías, K. Reich, A. Armstrong, 2019, EMJ Dermatology.

Latest Highlights from Guselkumab in Psoriasis

A. Armstrong, K. Reich, A. Blauvelt, 2019 .

K. Reich, M. Radtke, I. Schäfer, 2022 .

Nail psoriasis as a severity indicator: results from the PsoReal study.

K. Reich, M. Augustin, M. Radtke, 2010, Patient related outcome measures.

SAT0267 Safety of Ustekinumab from the Placebo-Controlled Periods of Psoriatic Arthritis and Psoriasis Clinical Developmental Programs

B. Strober, A. Gottlieb, P. Rahman, 2013 .

Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study

M. Lebwohl, K. Papp, K. Reich, 2023, The Lancet Rheumatology.

056 Impact of ixekizumab on palmoplantar plaque psoriasis compared to placebo and etanercept: results from UNCOVER 2

D. Shrom, A. Menter, K. Reich, 2016 .

ixekizumab, a novel anti–il-17a antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis : 3232

T. Luger, K. Reich, K. Gordon, 2016 .

A. Deodhar, I. McInnes, K. Reich, 2019, Annals of the rheumatic diseases.

28095 Long-term safety of guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials with up to 5 years of treatment

C. Griffiths, K. Papp, K. Reich, 2021 .

33830 Prognostic factors for early PASI 100 response in psoriasis patients treated with guselkumab: Results from the GUIDE study

K. Schäkel, K. Asadullah, K. Reich, 2022, Journal of the American Academy of Dermatology.

European consensus statement on phenotypes of pustular psoriasis

L. Naldi, D. Lipsker, A. Costanzo, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[Nail psoriasis--an ignored disorder. Pathogenesis, diagnosis and therapy].

K. Reich, C. Kahl, B. Hansen, 2012, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

The genetic basis for most patients with pustular skin disease remains elusive

K. Schäkel, S. Kõks, H. Sticht, 2018, The British journal of dermatology.

Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient‐reported symptom and quality of life measures: Integrated analysis of three Upadacitinib phase 3 trials

J. Silverberg, K. Reich, M. Deleuran, 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.

Replication of LCE3C-LCE3B CNV as a risk factor for psoriasis and analysis of interaction with other genetic risk factors.

X. Estivill, T. Wienker, T. Becker, 2010, Journal of Investigative Dermatology.

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

A. Kimball, S. Green, K. Papp, 2017, The Lancet.

A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.

J. Ortonne, K. Papp, K. Reich, 2011, The New England journal of medicine.

A plaidoyer for the use of human skin xenotransplant mouse models in preclinical psoriasis research

K. Reich, A. Keren, A. Gilhar, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

[Psoriasis--clinical picture and current therapy].

K. Reich, K. Shakery, 2009, Medizinische Monatsschrift fur Pharmazeuten.

Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo‐controlled phase IIa study

K. Reich, M. Binks, M. Simeoni, 2016, The British journal of dermatology.

Development and Validation of a Melanoma Risk Score Based on Pooled Data from 16 Case–Control Studies

Tim K. Lee, A. Ziegler, J. Barrett, 2015, Cancer Epidemiology, Biomarkers & Prevention.

S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 1 – Systemic treatment

K. Reich, M. Sebastian, M. Augustin, 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

AB0759 FOUR-YEAR EFFICACY AND SAFETY OF GUSELKUMAB IN PSORIASIS PATIENTS WITH AND WITHOUT PSORIATIC ARTHRITIS: A POOLED ANALYSIS FROM VOYAGE 1 AND VOYAGE 2

K. Reich, P. Foley, Y. You, 2020 .

Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2.

M. Lebwohl, C. Griffiths, K. Reich, 2021, Journal of drugs in dermatology : JDD.

Neue Erkenntnisse zu Fumarsäureestern (Fumaderm®): Ergebnisse eines Experten‐Workshops

B. Bonnekoh, T. Gambichler, T. Luger, 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

15 Jahre Fumaderm®: Fumarsäureester für die systemische Behandlung der mittelschweren und schweren Psoriasis vulgaris

K. Reich, U. Mrowietz, U. Mrowietz, 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Nail psoriasis as a severity indicator: results from the PsoReal study

K. Reich, M. Augustin, M. Radtke, 2010, Patient related outcome measures.

group data base Scleroderma Trials And Research (EUSTAR) in systemic sclerosis - a report from the EULAR Clinical risk assessment of organ manifestations

Gianluigi, Wigley, A. Gabrielli, 2007 .

Histology and Serum Cytokine Responses in an Imported Rickettsia slovaca Infection, Germany.

K. Reich, D. Tappe, N. Booken, 2018, The American journal of tropical medicine and hygiene.

388 Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis

T. Luger, M. Ohtsuki, K. Reich, 2016 .

Interleukin‐17A: a unique pathway in immune‐mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis

B. Kirkham, A. Kavanaugh, K. Reich, 2014, Immunology.